The DAWN Camostat Trial for Ambulatory COVID-19 Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- 1306
Summary
- Conditions
- COVID-19
- SARS-CoV Infection
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 40 years and 125 years
- Gender
- Both males and females
Description
In patients aged 50 years and above and diagnosed with Covid-19 upon study entry, we will evaluate the efficacy of camostat on hospital admission or death within 30 days after randomisation. Participants will be randomly assigned to camostat or placebo using a computer generated randomisation proces...
In patients aged 50 years and above and diagnosed with Covid-19 upon study entry, we will evaluate the efficacy of camostat on hospital admission or death within 30 days after randomisation. Participants will be randomly assigned to camostat or placebo using a computer generated randomisation process. Participants will be treated for 7 days, and follow-up will be 30 days.
Tracking Information
- NCT #
- NCT04730206
- Collaborators
- Universiteit Antwerpen
- University Ghent
- Université de Liège
- Vrije Universiteit Brussel
- Investigators
- Not Provided
Get Well Soon